GLP1R and obesity due to melanocortin 4 receptor deficiency: This review underscores key emerging concepts, such as the pathophysiological relevance of IPF, the interface between obesity and immunometabolism in pancreatic pathology, and the therapeutic potential of modern weight loss agents, including GLP-1 receptor agonists and dual incretin therapies.